The relationship between basal serum tumor necrosis factor alpha (TNFa) levels and peripheral tissue (muscle) sensitivity to insulin was examined in 63 subjects with normal glucose tolerance (NGT), 18 subjects with impaired glucose tolerance (IGT), and 123 patients with type 2 diabetes mellitus (T2DM). The BMI was similar in NGT (28.8 AE 0.7 kg=m 2 ), IGT (31.1 AE 1.0), and T2DM (30.0 AE 0.4) groups. The fasting serum TNFa concentration in T2DM (4.4 AE 0.2 pg=ml) was significantly higher than in NGT (3.1 AE 0.2) and IGT (3.4 AE 0.2; both P < 0.05). In T2DM the fasting plasma glucose (FPG ¼ 183 AE 5 mg=dl) and insulin (FPI ¼ 17 AE 1 mU=ml) concentrations were significantly higher than in NGT (FPG ¼ 95 AE 1; FPI ¼ 10 AE 1) and IGT (FPG ¼ 100 AE 2; FPI ¼ 13 AE 1; all P < 0.01). The rate of total body insulin-mediated glucose disposal (Rd; 40 mU=m 2 min euglycemic insulin clamp in combination with 3 H-glucose) was reduced in T2DM (102 AE 3 mg=m 2 min) compared with NGT (177 AE 10) and IGT (151 AE 14; both P < 0.01). The serum TNFa concentration was inversely correlated with Rd (r ¼ 70.47, P < 0.0001) and positively correlated with both FPG (r ¼ 0.32, P ¼ 0.004) and FPI (r ¼ 0.32, P ¼ 0.004) in NGT plus IGT. No correlation was observed between serum TNFa and Rd (r ¼ 70.02), FPG (r ¼ 0.15), or FPI (r ¼ 0.15) in T2DM. In stepwise multiple regression analysis using age, sex, BMI, FPG, FPI and serum TNFa concentration as independent variables, only BMI and serum TNFa concentration were significant and independent predictors of Rd (r 2 ¼ 0.29, P < 0.0001) in the NGT plus IGT group, while FPG and FPI were significant and independent predictors of Rd (r 2 ¼ 0.13, P < 0.0001) in T2DM. These results suggest that: (i) an increase in circulating TNFa concentration is associated with peripheral insulin resistance and increased plasma glucose and insulin levels prior to the onset of type 2 diabetes; and (ii) the further deterioration in peripheral insulin resistance in T2DM (compared with NGT and IGT) is unrelated to the increase in serum TNFa concentration.
Introduction
Reduced insulin-mediated glucose disposal is a dominant metabolic feature of obesity and type 2 diabetes mellitus, 1 and the close association between obesity and type 2 diabetes mellitus is well established. 2, 3 It has been suggested that tumor necrosis factor alpha (TNFa) may play a role in the peripheral tissue (primarily muscle) resistance to insulin in obese subjects and in patients with type 2 diabetes mellitus (T2DM). 4 -6 TNFa is synthesized and secreted by adipocytes 6 and elevated expression of TNFa mRNA in adipocytes is a common feature of genetically obese=insulin resistance rodent models 5 and human obesity. 4, 7 In vitro and in vivo studies in animals have shown that TNFa produces insulin resistance by inhibiting insulin receptor and IRS-1 tyrosine phosphorylation, leading to an impairment in phosphoinositol-3 kinase activity. 8 -10 Conversely, infusion of TNFa receptor antibody has been shown to improve insulin resistance in the Zucker fa=fa rats. 6 However, the infusion of TNFa neutralizing antibody 11, 12 in obese type 2 diabetic patients had no effect on insulin sensitivity. Furthermore, despite the strong evidence for an association between TNFa and insulin resistance in animal models of obesity and diabetes, it remains controversial whether circulating TNFa levels are elevated in T2DM, independent of obesity, and whether, if elevated, the increased serum TNFa concentration is related to the peripheral tissue resistance to insulin.
Nilsson et al 13 reported that the plasma TNFa concentration was increased by 23% in lean T2DM who displayed moderate insulin resistance and by 51% in obese T2DM with more severe insulin resistance. They also demonstrated an inverse relationship between the plasma TNFa concentration and insulin sensitivity in control and diabetic subjects. However, the number of subjects in each group was relatively small and the BMI in the diabetic and control groups differed by almost 9 kg=m 2 , making it difficult to distinguish between the separate contributions of insulin resistance, diabetes and obesity to the elevated plasma TNFa concentrations. Moreover, the rate of glucose disposal during the insulin clamp was expressed per kg body weight, causing a marked underestimation of insulin sensitivity in more obese diabetic subjects. Katsuki et al 14 reported that serum TNFa concentrations were elevated in obese T2DM, but not in lean T2DM. These authors found no relationship between the insulin sensitivity index and serum TNFa concentrations, but again the number of subjects in each group was quite small. Lastly, Zinman et al 15 reported that the serum TNFa concentration was elevated in T2DM but, after adjustment for the severity of insulin resistance (HOMA-R), it was not higher than in control subjects. The reasons for these conflicting results are multiple and include: the small number of subjects who were studied; different methods for measuring and expressing insulin sensitivity; and failure to take into account the separate effects of obesity, diabetes and severity of insulin resistance.
In the present study we have measured the serum TNFa concentration in a large number of subjects with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and type 2 diabetes mellitus (T2DM) with similar degrees of obesity and related the serum TNFa concentration to total body insulin-mediated glucose disposal, measured with the euglycemic insulin clamp technique.
Methods

Subjects
Two hundred and four subjects participated in the study, and they were divided into three group based upon the revised ADA criteria for the diagnosis of diabetes: 16 
Hyperinsulinemic euglycemic clamp
Insulin sensitivity was assessed with the euglycemic insulin clamp technique, as previously described. 17 At 07:30 h, Table 1 Clinical and metabolic characteristics of subjects with normal glucose tolerance (NGT), subjects with impaired glucose tolerance (IGT), and subjects with type 2 diabetes Type 2 diabetes TNF a and insulin resistance in type 2 diabetes Y Miyazaki et al following a 10 -12 h overnight fast, a catheter was placed into an antecubital vein for the infusion of all test substances. A second catheter for blood withdrawal was placed retrogradely into a vein on the dorsum of the hand, which was then placed in a heated box (60 C). At 08:00 h, a primed (25 mCi Â FPG=100) continuous (0.25 mCi=min) infusion of 3 H-3-glucose was started at time 7180 min (7120 min in nondiabetic subjects) and continued throughout the study. Baseline blood samples for determination of plasma glucose and insulin concentrations and plasma tritiated glucose radioactivity were drawn at 730, 720, 710, 75 and 0 min. Serum TNFa and plasma leptin samples were obtained at 720, 710 and 0 min. At time zero, a primed-continuous infusion of human regular insulin (Novolin, Novo Nordisk Pharmaceuticals, Princeton, NJ, USA) was started at a rate of 40 mU=min m 2 body surface area and continued for 120 min. After initiation of the insulin infusion, a variable infusion of 20% dextrose was adjusted to maintain the plasma glucose concentration at 90 mg=dl. In diabetic subjects the plasma glucose concentration was allowed to drop until it reached 90 mg=dl, at which level it was maintained by 20% dextrose. In all diabetic subjects the plasma glucose goal (90 mg=dl) was reached by 90 min. Throughout the insulin clamp, blood samples for determination of plasma glucose concentration were drawn every 5 min, and blood samples for determination of plasma insulin and 3 H-3-glucose specific activity were collected every 10 -15 min.
Assays
Plasma glucose was measured at bedside using the glucose oxidase method (Glucose Analyzer 2, Beckman Instruments Inc., Fullerton, CA, USA). Plasma insulin (Diagnostic Products Corporation, Los Angeles, CA, USA) was measured by radioimmunoassay. Tritiated glucose specific activity was determined in deproteinized plasma samples. Fasting serum TNFa concentration was determined with a very sensitive sandwich ELISA kit for human TNFa (Quantikine, R&D Systems, Minneapolis, MN, USA). This assay has a lower limit of detection of 0.5 pg=ml and intra-and inter-assay CVs of 5.7 and 7.5%, respectively. Fasting plasma leptin concentration was determined by radioimmunoassay (Linco Research Inc., St Charles, MO, USA).
Calculations
Under steady-state conditions, the rate of endogenous glucose appearance (R a ) is equal to the rate of total body glucose disposal (R d ¼ R a ) and is calculated as the 3 H-3-glucose infusion rate (dpm=min) divided by the steady-state plasma 3 H-3-glucose specific activity (dpm=mg). During the insulin clamp, non-steady conditions prevail and R a and R d were calculated from Steele's equation, 18 using a pool fraction of 0.65 and glucose distribution volume 250 ml=kg body weight. Because of differences in body weight amongst individuals, all R d data are expressed per m 2 .
Data analysis
Data are presented as the mean AE standard error. Comparison between groups was performed using analysis of variance with Schaffe's post hoc testing; when appropriate, these comparisons were adjusted for continuous variables by regression analysis. Linear or logarithmic (for nonlinearly distributed data) regression analysis was used to examine the relationships between serum TNFa concentration and other variables. A stepwise multiple regression analysis was performed to determine which variables contributed to total body insulin-mediated glucose disposal (R d ). A P-value less than 0.05 was considered to be statistically significant.
Results
In type 2 diabetic patients the rate of total body insulinmediated glucose disposal (R d ¼ 102 AE 3 mg=m 2 min) was significantly decreased and the fasting serum TNFa concentration (4.4 AE 0.2 pg=ml) was significantly increased compared to the NGT and IGT groups after adjustment for age and sex (Table 1 ). The body mass index was similar in all three groups ( Table 1 ). The increase in serum TNFa concentration in T2DM compared with NGT and IGT groups remained significant after adjustment for differences in Rd, as well as for differences in age, between groups. The fasting plasma leptin concentrations were similar among the three groups and within each group the plasma leptin concentration was higher in female compared to male subjects (all P < 0.05; Table 1 ). There were no differences in serum TNFa concentration between male and female subjects in the NGT (3.2 AE 0.3 vs 3.1 AE 0.2 pg=ml), IGT (3.4 AE 0.4 vs 3.3 AE 0.2) and T2DM group (4.6 AE 0.2 vs 4.2 AE 0.2) groups. Basal endogenous glucose production (EGP) was 74 AE 2, 73 AE 3 and 79 AE 2 mg=m 2 Á min in the NGT, IGT and T2DM groups, respectively (P < 0.10, T2DM vs NGT and IGT). The failure to observe a statistically significant increase in basal EGP in the type 2 diabetics most likely is explained by the higher fasting plasma insulin concentration in this group. There was no relationship between the serum TNFa concentration and the basal rate of EGP in the NGT plus IGT or in the T2DM groups. When all subjects were analyzed collectively, there was an inverse correlation between serum TNFa concentration and R d (r ¼ 70.407, P < 0.0001), and modest positive correlations between serum TNFa concentration and FPG (r ¼ 0.353, P < 0.0001) and FPI (r ¼ 0.290, P < 0.0001; Figures 1 -3) . Within the T2DM group alone, no significant correlations were observed between the serum TNFa concentration and R d or with the FPG and FPI concentrations. Significant correlations were still observed in the NGT plus IGT group (Figures  1 -3) . When diet-and sulfonylurea-treated diabetic subjects were analyzed separately, no significant correlations between serum TNFa concentration and R d (r ¼ 0.14, P ¼ 0.3 and r ¼ 0.11, P ¼ 0.3), FPG (r ¼ 0.01, P ¼ 0.9 and r ¼ 0.23, P ¼ 0.06) or FPI (r ¼ 0.22, P ¼ 0.11 and r ¼ 0.07, P ¼ 0.6; diet-and sulfonylurea-treated patients, respectively) TNF a and insulin resistance in type 2 diabetes Y Miyazaki et al were observed. Body mass index (BMI) did not correlate significantly with serum TNFa concentration either in the NGT plus IGT group (r ¼ 0.045, P ¼ 0.7) or in the T2DM group (r ¼ 0.054, P ¼ 0.6). BMI strongly correlated with the plasma leptin concentration in the NGT plus IGT (male: r ¼ 0.76, P < 0.0001; female: r ¼ 0.75, P < 0.0001) and T2DM (male: r ¼ 0.65, P < 0.0001; female: r ¼ 0.59, P < 0.0001) groups. There was no correlation between the serum TNFa concentration and the plasma leptin concentration (r ¼ 0.004, P ¼ 0.9). In stepwise multiple regression analysis using age, sex, BMI, FPG, FPI, serum TNFa concentration and plasma leptin concentration as independent variables, only BMI and serum TNFa concentration were significant and independent contributors to the variation in R d (adjusted r 2 ¼ 0.29, P < 0.0001) in the NGT plus IGT. In the T2DM group only FPG and FPI were significant and independent contributors to the variation of R d (adjusted r 2 ¼ 0.13, P < 0.0001).
Discussion
In the present study, we examined whether circulating TNFa levels are increased in type 2 diabetic patients and, if so, whether they are related to the severity of whole body insulin resistance. Our results demonstrate that, compared to age=gender=BMI matched nondiabetic individuals, T2DM subjects had significantly higher circulating TNFa concentrations (Table 1) . However, the elevated TNFa concentration in T2DM patients was not correlated with the rate of whole body insulin-mediated glucose disposal (R d ). In contrast, nondiabetic individuals displayed a significant inverse correlation between serum TNFa concentration and Rd. The inverse correlation between TNFa levels and insulin sensitivity in NGT and IGT subjects, independent of obesity= age=gender, is consistent with a potential role of circulating TNFa in the regulation of insulin action. The failure to observe a significant correlation between serum TNFa and insulin-mediated glucose disposal in type 2 diabetic patients does not exclude a role for TNFa in the development of insulin resistance in this group. The present results clearly demonstrate that circulating TNFa levels are increased in T2DM. It is possible that, by the time that overt diabetes is manifest, other pathogenic factors, ie hyperglycemia and Figure 1 Correlation between serum TNFa concentration and rate of total body insulin-mediated glucose disposal (R d ) in subjects with normal glucose tolerance (NGT; s), subjects with impaired glucose tolerance (IGT; Â u), and patients with type 2 diabetes mellitus (T2DM; j). Figure 2 Correlation between serum TNFa concentration and fasting plasma glucose concentration (FPG) in subjects with normal glucose tolerance (NGT; s), subjects with impaired glucose tolerance (IGT; Â u), and patients with type 2 diabetes mellitus (T2DM; j). Figure 3 Correlation between serum TNFa concentration and fasting plasma insulin concentration (FPI) in subjects with normal glucose tolerance (NGT; s), subjects with impaired glucose tolerance (IGT; Â u), and patients with type 2 diabetes mellitus (T2DM; j).
TNF 19, 20 hyperinsulinemia, 19, 21 increased plasma FFA concentration, 19, 22 worsening obesity, etc, play a more important role in the development of insulin resistance and obscure the correlation between serum TNFa concentration and insulin resistance that was observed in nondiabetic individuals. Consistent with this hypothesis, both FPG and FPI concentrations were found to be correlated with the severity of insulin resistance in T2DM. Most previous studies that have reported a significant association between serum TNFa and insulin resistance have employed a combined analysis of diabetic and nondiabetic subjects. 13, 15, 23 Similarly, when we combined our diabetic and nondiabetic subjects, a significant correlation between TNFa and insulin resistance was observed (r ¼ 70.407, P < 0.001). Only one previous paper 14 has examined the relationship between insulin resistance and serum TNFa in obese type 2 diabetics and, consistent with our results, they also failed to find a significant relationship between these two variables. It should be noted, however, that the number of diabetic subjects in this study was small (n ¼ 12).
Another potential explanation for the lack of correlation between the severity of insulin resistance and serum TNFa concentration relates to the local autocrine=paracrine action of TNFa. In both man and animals TNFa is synthesized by adipocytes, but it may not be released into the circulation from the fat cell. 5, 24 Rather, it exerts its action locally. Consequently, it can induce insulin resistance in muscle and=or liver 25 -27 in the absence of any increase in circulating serum TNFa levels. TNFa also is synthesized and secreted by activated macrophages and lymphocytes, 28 and it has been suggested that type 2 diabetes may represent a state of chronic inflammation. 29 Consistent with this hypothesis, neutralization of TNFa with a soluble TNF receptor-IgG fusion protein has been shown to augment insulin-stimulated autophosphorylation of both the insulin receptor and insulin receptor substrate-1 in muscle and fat. 30 Similarly, inhibition of TNFa activity with a replication-incompetent adenovirus vector in the obese Zucker rat improves hepatic and muscle sensitivity by enhancing the insulin receptor signal cascade. 26, 31 However, in obese, insulin-resistant diabetic and nondiabetic humans, 11, 12 neutralization of circulating TNFa levels failed to improve glycemic control or insulin sensitivity. It is possible, however, that the neutralizing antibodies did not reach the cell surface and interfere with the local paracrine effects of TNFa secreted by fat cells and=or macrophages=lymphocytes. 24, 28 In the present study, BMI did not correlate with the serum TNFa concentration in either nondiabetic or diabetic subjects. In contrast, strong correlations were observed between BMI and plasma leptin concentration in both nondiabetic or diabetic subjects. This later observation is consistent with numerous previous publications which have documented a strong correlation between fat mass and plasma leptin concentration. 32, 33 However, leptin improves insulin sensitivity 34 and the increased plasma leptin levels in obesity and T2DM cannot explain the insulin resistance in these two common metabolic disorders. TNFa is expressed in adipose tissue, 5 and its expression is increased in obesity 4 -7 and decreased after weight loss. 4, 7, 35, 36 These and many other studies have documented that adipose tissue is an important source of circulating TNFa. However, unlike plasma leptin, we failed to observe a significant relationship between serum TNFa concentration and BMI. Similar findings have been reported by others. 14, 15 Several explanations could account for the lack of correlation between BMI and serum TNFa concentration. It is well established that there are regional differences in protein production by human adipose tissue. Thus, leptin expression and secretion is increased in subcutaneous adipose tissue compared with visceral adipose tissue, 37 and it has been reported that only subcutaneous leptin production is correlated with circulating leptin levels. 38 Although some studies have failed to demonstrate any regional variations in TNFaproduction by human adipose tissue, 37 several papers have reported that serum TNFa levels were associated with only abdominal obesity 39 or with visceral fat, 14 but not with BMI or subcutaneous fat. In the present study we did not measure the waist to hip ratio or quantitate the amount of visceral fat. Another potential explanation for the failure to observe any relationship between BMI and serum TNFa relates to the multiple sources of circulating TNFa. TNFa also is synthesized and secreted by muscle 40 and lymphocytes and macrophages. 28 In vitro studies 40 have demonstrated that TNFa is expressed by human muscle, and that TNFa expression is higher in muscle from subjects with insulin resistance and type 2 diabetes mellitus. In addition, both hyperglycemia 41 and hyperinsulinemia 42 have been shown to enhance the production of TNFa from monocytes and macrophages in vitro. Lastly, some studies have reported an age-related increase in TNFa levels. 43 However, even after adjustment for age, the TNFa concentration remained elevated in the diabetic group.
In summary, the present results demonstrate that: (i) an increase in circulating TNFa concentration is associated with peripheral insulin resistance and increased plasma glucose and insulin levels prior to the onset of type 2 diabetes; (ii) serum TNFa levels are elevated in type 2 diabetic patients and are unrelated to the degree of obesity (BMI); (iii) the increased serum TNFa concentration in type 2 diabetic individuals is not correlated with the severity of insulin resistance; this lack of correlation may be explained by the presence of hyperglycemia, hyperinsulinemia or other factors which have a stronger impact on peripheral insulin sensitivity in type 2 diabetes mellitus.
